Adebrelimab

Generic Name
Adebrelimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2247114-85-6
Unique Ingredient Identifier
1XBY50W1OX
Background

Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication

用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer

Early Phase 1
Not yet recruiting
Conditions
NSCLC
Interventions
Drug: mRNA Neoantigen Vaccine
Drug: Adebrelimab
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
40
Registration Number
NCT06735508
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
448
Registration Number
NCT06699576

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC

First Posted Date
2024-11-12
Last Posted Date
2024-11-12
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
70
Registration Number
NCT06684158
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC

First Posted Date
2024-11-04
Last Posted Date
2024-11-05
Lead Sponsor
Jinming Yu
Target Recruit Count
524
Registration Number
NCT06672133

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Harbin Medical University
Target Recruit Count
68
Registration Number
NCT06648525
Locations
🇨🇳

Harbin Medical University, Harbin, Heilongjiang, China

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

First Posted Date
2024-10-01
Last Posted Date
2024-11-13
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
560
Registration Number
NCT06618664
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC

First Posted Date
2024-09-24
Last Posted Date
2024-09-24
Lead Sponsor
Sichuan University
Target Recruit Count
202
Registration Number
NCT06610734

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

First Posted Date
2024-09-13
Last Posted Date
2024-09-13
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
350
Registration Number
NCT06594874
Locations
🇨🇳

Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

First Posted Date
2024-09-12
Last Posted Date
2024-09-12
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06592625
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy